SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-005067
Filing Date
2020-01-10
Accepted
2020-01-10 08:11:14
Documents
12
Period of Report
2020-01-10
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d864228d8k.htm   iXBRL 8-K 27292
  Complete submission text file 0001193125-20-005067.txt   147014

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rvnc-20200110.xsd EX-101.SCH 3067
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvnc-20200110_lab.xml EX-101.LAB 17374
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvnc-20200110_pre.xml EX-101.PRE 10951
8 EXTRACTED XBRL INSTANCE DOCUMENT d864228d8k_htm.xml XML 3238
Mailing Address 7555 GATEWAY BLVD. NEWARK CA 94560
Business Address 7555 GATEWAY BLVD. NEWARK CA 94560 510-742-3400
Revance Therapeutics, Inc. (Filer) CIK: 0001479290 (see all company filings)

IRS No.: 770551645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36297 | Film No.: 20519477
SIC: 2834 Pharmaceutical Preparations